Allergy Therapeutics PLC Director/PDMR Shareholding (8138V)
November 07 2017 - 7:59AM
UK Regulatory
TIDMAGY
RNS Number : 8138V
Allergy Therapeutics PLC
07 November 2017
The announcement released by Allergy Therapeutics plc entitled
"Director/ PDMR Shareholding" on 7 November 2017 at 11:54
incorrectly stated the exercise price as GBP0.0001 per share. The
correct exercise price is GBP0.001. All other figures remain
unchanged. The correct figure is included in the reissued
announcement below:
07 November 2017
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Grant of Options under Long Term Incentive Plan
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, announces
that certain performance conditions attaching to provisional awards
("Awards") made pursuant to the Company's Long Term Incentive Plan
("LTIP") for the three years ended 30 June 2017, details of which
were announced on 5 November 2014, have been met. Consequently,
Allergy Therapeutics has today granted to certain employees of the
Company, including a PDMR, low cost options ("Options") over the
Company's ordinary shares of 0.1 pence each ("Ordinary Shares") in
replacement for the Awards made under the LTIP. Details of the
grant of Options to the PDMR are as follows:
Director Number of Total number Total remaining
Ordinary of Ordinary number of Ordinary
Shares over Shares over Shares provisionally
which Options which Options awarded under
granted granted LTIPs
Manuel Llobet,
Chief Executive
Officer 626,399 626,399 1,690,000
The Options have been granted in accordance with the LTIP rules
with an exercise price of GBP0.001 per share, and can be exercised
between 07 November 2017 and 06 November 2027.
Notification of transactions of persons discharging managerial
responsibilities and persons closely associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ------------------------------------------------------------
a) Name Manuel Llobet
--- ----------------- -----------------------------------------
2 Reason for the notification
Grant of Options
--- ------------------------------------------------------------
a) Position/status Chief Executive Officer
--- ----------------- -----------------------------------------
b) Initial Initial notification
notification
/Amendment
--- ----------------- -----------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ------------------------------------------------------------
a) Name ALLERGY THERAPEUTICS PLC
--- ----------------- -----------------------------------------
b) LEI 213800PQ7AHK7KGVOE23
--- ----------------- -----------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ------------------------------------------------------------
a) Description Options over Ordinary Shares of GBP0.001
of the each
financial
instrument,
type of
instrument
GB00B02LCQ05
Identification
code
--- ----------------- -----------------------------------------
b) Nature Grant of Options
of the
transaction
--- ----------------- -----------------------------------------
c) Price(s) Exercise Volume
and volume(s) Price
---------- --------
GBP0.001 626,399
---------- --------
--- ----------------- -----------------------------------------
d) Aggregated
information
- Aggregated
volume 626,399 Options
- Price GBP0.001
--- ----------------- -----------------------------------------
e) Date of 07 November 2017
the transaction
--- ----------------- -----------------------------------------
f) Place of London Stock Exchange, AIM
the transaction
--- ----------------- -----------------------------------------
This announcement contains insider information for the purposes
of Article 7 of Regulatory (EU) No596/2014.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical group focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBDBDBRUGBGRR
(END) Dow Jones Newswires
November 07, 2017 07:59 ET (12:59 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
